To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Identifying microRNAs that can Serve as Biomarkers for Prostate Cancer
Read time: Less than a minute
Using Fluidigm Corporation's BioMark™ System and Digital Array™ integrated fluidic circuits (IFCs), researchers from the University of California San Francisco have identified serum microRNAs that can serve as biomarkers for prostate cancer.
To do this, the UCSF research group designed their own microRNA preAMP and PCR primers specifically to be used on the BioMark platform. Through this method, they were able to identify mRNA signatures that correlate with prognosis.
One in six men will be diagnosed with prostrate cancer during their lifetime. Recent prostate specific antigen (PSA) based screening trials indicate an urgent need for novel and non-invasive biomarker identification strategies to improve the prediction of prostate cancer behaviour. Non-coding microRNAs (miRNAs) in the serum and plasma have been shown to have potential as non-invasive markers for physiological and pathological conditions.
To identify serum miRNAs that diagnose and correlate with prognosis of prostate cancer, the researchers at UCSF developed a multiplex quantitative reverse transcription PCR (qRT-PCR) method involving purification of multiplex PCR products followed by uniplex analysis on a Fluidigm microfluidics chip to evaluate 384 human miRNAs.
Using Dgcr8 and Dicer knockout (small RNA - deficient) mouse ES cells (mESC) as the benchmark, the researchers confirmed the validity of their technique, while uncovering a significant lack of accuracy in previously published methods.
Profiling 48 sera from healthy men and untreated prostate cancer patients with differing CAPRA (Cancer of the Prostate Risk Assessment) scores, UCSF researchers identified miRNA signatures that allowed them to diagnose cancer patients and correlate with prognosis. These serum signatures included oncogenic and tumor suppressive miRNAs suggesting functional roles in prostate cancer progression.
To do this, the UCSF research group designed their own microRNA preAMP and PCR primers specifically to be used on the BioMark platform. Through this method, they were able to identify mRNA signatures that correlate with prognosis.
One in six men will be diagnosed with prostrate cancer during their lifetime. Recent prostate specific antigen (PSA) based screening trials indicate an urgent need for novel and non-invasive biomarker identification strategies to improve the prediction of prostate cancer behaviour. Non-coding microRNAs (miRNAs) in the serum and plasma have been shown to have potential as non-invasive markers for physiological and pathological conditions.
To identify serum miRNAs that diagnose and correlate with prognosis of prostate cancer, the researchers at UCSF developed a multiplex quantitative reverse transcription PCR (qRT-PCR) method involving purification of multiplex PCR products followed by uniplex analysis on a Fluidigm microfluidics chip to evaluate 384 human miRNAs.
Using Dgcr8 and Dicer knockout (small RNA - deficient) mouse ES cells (mESC) as the benchmark, the researchers confirmed the validity of their technique, while uncovering a significant lack of accuracy in previously published methods.
Profiling 48 sera from healthy men and untreated prostate cancer patients with differing CAPRA (Cancer of the Prostate Risk Assessment) scores, UCSF researchers identified miRNA signatures that allowed them to diagnose cancer patients and correlate with prognosis. These serum signatures included oncogenic and tumor suppressive miRNAs suggesting functional roles in prostate cancer progression.
